/PRNewswire/ Tris Pharma, Inc. (Tris) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that DYANAVEL® XR.
/PRNewswire/ Tris Pharma, Inc. (Tris) announced today that the U.S. Food and Drug Administration has approved Dyanavel XR (amphetamine), extended release.
Share this article
Share this article
MONMOUTH JUNCTION, N.J., April 29, 2021 /PRNewswire/ Tris Pharma, Inc. ( Tris ), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related conditions, today announced that it has acquired Park Therapeutics, a company developing a unique, first-in-class, investigational NCE for the treatment of pain which is Phase III-ready.
Studies have demonstrated the potential for the NCE to provide strong efficacy in nociceptive and neuropathic pain, while maintaining a highly differentiated safety profile results from its unique, first-in-class dual mechanism of action as a highly potent agonist of the nociceptin/orphanin FQ (NOP), DOP and MOP receptors and partial agonist of KOP receptors. The drug has been studied extensively in both Europe and the US in approximately 2,000 subjects in